Switching from Levetiracetam (Keppra) to Brivaracetam (Briviact)
An overnight switch from levetiracetam to brivaracetam at a conversion ratio of 10:1 to 15:1 is safe, well-tolerated, and the recommended approach for most patients. 1, 2, 3
Conversion Protocol
Recommended Conversion Ratio
- Use a 10:1 to 15:1 conversion ratio (levetiracetam:brivaracetam)
- For example: Levetiracetam 1000 mg/day converts to brivaracetam 100 mg/day (10:1) or 67-100 mg/day (15:1)
- The FDA-approved starting dose for adults is 50 mg twice daily (100 mg/day), with a range of 50-200 mg/day 1
Switching Method
Perform an overnight (immediate) switch rather than gradual cross-titration:
- Stop levetiracetam on day 1
- Start brivaracetam at the calculated dose on day 2
- No titration period is required when initiating brivaracetam 1
- This approach has been validated in multiple real-world studies showing excellent safety and tolerability 2, 4
Dosing Specifics
For adults (≥16 years):
- Initial dose: 50 mg twice daily (100 mg/day)
- Maintenance range: 25-100 mg twice daily (50-200 mg/day)
- Adjust based on clinical response and tolerability 1
For pediatric patients weighing ≥50 kg:
- Follow adult dosing guidelines
- For patients <50 kg, use weight-based dosing per FDA label 1
Expected Outcomes
Seizure Control
- Retention rates: 88.6% at 6 months, 83.9% at 12 months 5
- Seizure freedom: 72.7% at 6 months, 58.1% at 12 months in conversion monotherapy 5
- Overall seizure frequency improves in 26.8% of patients, remains stable in 61%, and worsens in only 12.2% 2
Neuropsychiatric Adverse Effects
This is the primary reason for switching and shows the most dramatic improvement:
- 76% of patients experience improvement in levetiracetam-related neuropsychiatric symptoms after switching to brivaracetam 2
- Improvements are particularly notable in irritability, aggression, mood disturbances, and behavioral problems 6, 4
- In pediatric patients, 60% report improved tolerability, especially regarding mood, attention, and irritability 6
Safety Profile
- Discontinuation rate: Only 4.5-19.5% due to adverse events 5, 2
- Most common adverse events: somnolence, dizziness, fatigue (similar to levetiracetam but generally better tolerated) 2, 7
- No serious adverse events reported in most switching studies 2
Special Considerations
Patients with Prior Psychiatric History
- A history of psychiatric illness predicts neuropsychiatric side effects with levetiracetam but NOT with brivaracetam (p=0.001) 4
- This makes brivaracetam particularly valuable for patients with baseline psychiatric comorbidities
Patients with Intellectual Disabilities
- Switching is equally safe and effective in patients with intellectual disabilities compared to those without 4
- Over 90% remain on brivaracetam after 12 months regardless of intellectual disability status 4
Hepatic Impairment
If hepatic impairment is present:
- Reduce initial dose to 25 mg twice daily (50 mg/day)
- Maximum maintenance dose: 75 mg twice daily (150 mg/day) 1
Concomitant Rifampin
- Double the brivaracetam dose (increase by up to 100%) if patient is taking rifampin 1
Common Pitfalls to Avoid
Do not perform gradual cross-titration - The overnight switch is both safe and preferred, avoiding prolonged exposure to levetiracetam's neuropsychiatric effects 2
Do not use a 1:1 conversion ratio - This will result in overdosing; the correct ratio is 10:1 to 15:1 3
Do not expect immediate seizure improvement - While neuropsychiatric symptoms often improve rapidly, seizure control may take several weeks to assess 5
Do not abruptly discontinue brivaracetam if switching back - Taper over 1-4 weeks depending on dose to minimize seizure risk 1
Be aware that 19% may experience worsened adverse effects - Have a plan to switch back to levetiracetam if needed 6
Monitoring After Switch
- Assess neuropsychiatric symptoms within the first week (most improvements occur rapidly)
- Evaluate seizure control at 3 months, 6 months, and 12 months
- Monitor for somnolence, dizziness, and fatigue (most common adverse events)
- Consider dose adjustment based on clinical response between 50-200 mg/day 1